ZYUS:CA:TSV-ZYUS Life Sciences Corporation (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1.1

Change

+0.06 (+5.77)%

Market Cap

USD 0.07B

Volume

4.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

-0.34 (-3.45%)

USD 0.11B
LOVE:CA Cannara Biotech Inc

-0.01 (-1.37%)

USD 0.06B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

+0.01 (+1.05%)

USD 0.06B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.02 (-4.08%)

USD 0.03B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.03B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
MPH:CA Medicure Inc

-0.01 (-0.93%)

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 0.01B

ETFs Containing ZYUS:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.22% 72% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.22% 72% C 67% D+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 95% A 90% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.